After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

When Aveo Oncology scored European approval in 2017 for its lead cancer drug tivozanib — despite the treatment’s chequered past — a comeback story was in the making. New pivotal data could now threaten that approval, and the company’s investors are losing patience.